Drawz, P., et al. Chronic kidney disease. Ann. Intern. Med. 162(11), ITC1–16 (2015).
Glassock, R. J. et al. The global burden of chronic kidney disease: Estimates, variability and pitfalls. Nat. Rev. Nephrol. 13(2), 104–114 (2017).
Ruiz-Ortega, M. et al. Targeting the progression of chronic kidney disease. Nat. Rev. Nephrol. 16(5), 269–288 (2020).
Chen, T. K. et al. Chronic kidney disease diagnosis and management: A review. JAMA. 322(13), 1294–1304 (2019).
Schwarz, S. et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 1(4), 825–831 (2006).
Hu, L. et al. Mineral bone disorders in kidney disease patients: The ever-current topic. Int. J. Mol. Sci. 23(20), 12223 (2022).
Pazianas, M. et al. Osteoporosis and chronic kidney disease-mineral and bone disorder (CKD–MBD): Back to basics. Am. J. Kidney Dis. 78(4), 582–589 (2021).
Mehrotra, R. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients. J. Ren. Nutr. 16(2), 100–118 (2006).
Cozzolino, M. et al. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. Ther. Clin. Risk Manag. 13, 679–689 (2017).
Yamada, S. et al. Role of chronic kidney disease (CKD)-mineral and bone disorder (MBD) in the pathogenesis of cardiovascular disease in CKD. J. Atheroscler. Thromb. 30(8), 835–850 (2023).
Ersoy, F. F. A short story of Klotho and FGF23: A deuce of dark side or the savior?. Int. Urol. Nephrol. 46(3), 577–581 (2014).
Neyra, J. A. et al. Potential application of klotho in human chronic kidney disease. Bone 100, 41–49 (2017).
Shiraki-Iida, T. et al. Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett. 424(1–2), 6–10 (1998).
Xu, Y. et al. Molecular basis of Klotho: From gene to function in aging. Endocr. Rev. 36(2), 174–193 (2015).
Dhayat, N. A. et al. Parathyroid hormone and plasma phosphate are predictors of soluble α-Klotho levels in adults of European descent. J. Clin. Endocrinol. Metab. 105(4), e1135-1143 (2020).
Oh, H. J. et al. Decreased circulating klotho levels in patients undergoing dialysis and relationship to oxidative stress and inflammation. Perit. Dial. Int. 35(1), 43–51 (2015).
Rodríguez, M. et al. FGF23 and mineral metabolism, implications in CKD–MBD. Nefrologia. 32(3), 275–278 (2012).
Evrard, S. et al. SFBC/SN joined working group on vascular calcifications. Vascular calcification: From pathophysiology to biomarkers. Clin. Chim. Acta. 438, 401–414 (2015).
Slatopolsky, E. The intact nephron hypothesis: The concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int. 79121, S3-8 (2011).
Moher, D. et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 339, b2535 (2009).
McGrath, T. A. et al. Recommendations for reporting of systematic reviews and meta-analyses of diagnostic test accuracy: A systematic review. Syst. Rev. 6(1), 194 (2017).
Stang, A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25(9), 603–605 (2010).
Wilson, D. B. et al. The role of method in treatment effectiveness research: Evidence from meta-analysis. Psychol. Methods 6(4), 413–429 (2001).
Buiten, M. S. et al. Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients. BMC Nephrol. 15, 197 (2014).
Desbiens, L. C. et al. FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: A case-control study. Osteoporos. Int. 29(10), 2345–2353 (2018).
Khodeir, S. A. et al. Clinical significance of fibroblast growth factor-23 and soluble alpha klotho in different stages of chronic kidney disease. Saudi J. Kidney Dis. Transpl. 30(1), 108–118 (2019).
Koyama, D. et al. Soluble αKlotho as a candidate for the biomarker of aging. Biochem. Biophys. Res. Commun. 467(4), 1019–1025 (2015).
Liu, Q. F. et al. Plasma s-Klotho is related to kidney function and predicts adverse renal outcomes in patients with advanced chronic kidney disease. J. Investig. Med. 66(3), 669–675 (2018).
Pasaoglu, O. T. et al. FGF23, alpha-Klotho and vitamin D mediated calcium-phosphate metabolism in haemodialysis patients. J. Med. Biochem. 40(2), 160–166 (2021).
Rotondi, S. et al. Soluble α-Klotho serum levels in chronic kidney disease. Int. J. Endocrinol. 2015, 872193 (2015).
Seiler, S. et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int. 83(1), 121–128 (2013).
Chen, Y. et al. The clinical value of Klotho and FGF23 in cardiac valve calcification among patients with chronic kidney disease. Int. J. Gen. Med. 14, 857–866 (2021).
Kim, H. R. et al. Circulating α-klotho levels in CKD and relationship to progression. Am. J. Kidney Dis. 61(6), 899–909 (2013).
Kitagawa, M. et al. A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS ONE. 8(2), e56695 (2013).
Yokoyama, K. et al. Serum soluble α-klotho in hemodialysis patients. Clin. Nephrol. 77(5), 347–351 (2012).
Cai, H. et al. Serum soluble klotho level is associated with abdominal aortic calcification in patients on maintenance hemodialysis. Blood Purif. 40(2), 120–126 (2015).
Cai, H. et al. A decreased level of soluble klotho can predict cardiovascular death in no or mild abdominal aortic calcification hemodialysis patients. Front. Med. (Lausanne) 8, 672000 (2021).
Di Lullo, L. et al. Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease. Clin. Kidney J. 8(6), 732–736 (2015).
Lin, Y. et al. Association of serum klotho levels with different-staged vascular calcification status in patients with maintenance hemodialysis. BMC Nephrol. 23(1), 374 (2022).
Buchanan, S. et al. Klotho, aging, and the failing kidney. Front. Endocrinol. (Lausanne) 11, 560 (2020).
Zou, D. et al. The role of klotho in chronic kidney disease. BMC Nephrol. 19(1), 285 (2018).
Dalton, G. D. et al. New insights into the mechanism of action of soluble klotho. Front. Endocrinol. (Lausanne) 8, 323 (2017).
Tsuchiya, K. et al. Klotho/FGF23 axis in CKD. Contrib Nephrol. 185, 56–65 (2015).
Andrukhova, O. et al. Klotho lacks an FGF23-independent role in mineral homeostasis. J. Bone Miner. Res. 32(10), 2049–2061 (2017).
Hu, M. C. et al. Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 24(9), 3438–3450 (2010).
Kuro-O, M. The FGF23 and Klotho system beyond mineral metabolism. Clin. Exp. Nephrol. 21(Suppl 1), 64–69 (2017).
Hu, M. C. et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 22(1), 124–136 (2011).
Kuro-o, M. Klotho as a regulator of oxidative stress and senescence. Biol. Chem. 389(3), 233–241 (2008).
Ide, N. et al. In vivo evidence for a limited role of proximal tubular Klotho in renal phosphate handling. Kidney Int. 90(2), 348–362 (2016).
Levin, A. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 71(1), 31–38 (2007).
Kawai, M. The FGF23/Klotho axis in the regulation of mineral and metabolic homeostasis. Horm. Mol. Biol. Clin. Investig. 28(1), 55–67 (2016).
Cha, S. K. et al. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc. Natl. Acad. Sci. USA 105(28), 9805–9810 (2008).
Galitzer, H. et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77(3), 211–218 (2010).
Komaba, H. et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 77(3), 232–238 (2010).
Riancho, J. A. et al. Association of the F352V variant of the Klotho gene with bone mineral density. Biogerontology. 8(2), 121–127 (2007).
Marçais, C. et al. Circulating klotho associates with cardiovascular morbidity and mortality during hemodialysis. J. Clin. Endocrinol. Metab. 102(9), 3154–3161 (2017).
Chen, T. et al. The role and mechanism of α-klotho in the calcification of rat aortic vascular smooth muscle cells. Biomed. Res. Int. 2015, 194362 (2015).
Chalhoub, D. et al. Association of Serum klotho with loss of bone mineral density and fracture risk in older adults. J. Am. Geriatr. Soc. 64(12), e304–e308 (2016).
Kendrick, J. et al. The role of phosphorus in the development and progression of vascular calcification. Am. J. Kidney Dis. 58(5), 826–834 (2011).
Sakan, H. et al. Reduced renal α-Klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. PLoS ONE. 9(1), e86301 (2014).
Olauson, H. et al. Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet. 9(12), e1003975 (2013).
Kuro-o, M. et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 390(6655), 45–51 (1997).
Klinger, M. et al. Mortality predictor pattern in hemodialysis and peritoneal dialysis in diabetic patients. Adv. Clin. Exp. Med. 28(1), 133–135 (2019).
Hatakeyama, S. et al.Prognosis of elderly Japanese patients aged ≥80 years undergoing hemodialysis. Sci. World J. 2013, 693514 (2013).
Krishnasamy R, et al. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. BMC Nephrol. 18(1), 281 (2017).
Liu QF, et al. Plasma s-Klotho is related to kidney function and predicts adverse renal outcomes in patients with advanced chronic kidney disease. J Investig Med. 66(3), 669-675 (2018).
- The Renal Warrior Project. Join Now
- Source: https://www.nature.com/articles/s41598-024-54812-4